<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35295329</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1663-9812</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>13</Volume>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in pharmacology</Title>
          <ISOAbbreviation>Front Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Clinical Outcome and Medical Cost of Originator and Generic Antihypertensive Drugs: A Population-Based Study in Yinzhou, China.</ArticleTitle>
        <Pagination>
          <StartPage>757398</StartPage>
          <MedlinePgn>757398</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">757398</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2022.757398</ELocationID>
        <Abstract>
          <AbstractText><b>Background:</b> The substitution of generic drugs can effectively alleviate the rapid growth of drug costs; however, the clinical effectiveness and medical costs of originator products and generics were barely studied in China. <b>Objectives:</b> To compare the effectiveness of antihypertensive drugs and hypertension-related medical costs between originator and generic initiators in Yinzhou, China. <b>Methods:</b> We conducted a population-based retrospective cohort study using the Chinese Electronic Health Records Research in Yinzhou (CHERRY), from July 1, 2011, to December 31, 2018. Hypertension patients initiating with originator products were compared with patients initiating with generic counterparts. We used 1:1 propensity score matching to pair the two groups based on sociodemographic, clinical, and health service utilization variables. Cox proportional regression was adopted to compare the rate of hospitalization for hypertension-related cardiovascular disease between matched originator and generic initiators. Wilcoxon matched-pairs signed-rank test was used to compare annual hypertension-related medical costs. <b>Results:</b> Matched pairs (10,535) of patients were included in the comparative study of originator products and generics, corresponding to seven antihypertensive drugs including amlodipine, felodipine, nifedipine, irbesartan, losartan, valsartan, and metoprolol. The average age of patients included in the analysis was around 60 years (originator <i>vs</i>. generics initiators: from 59.0 <i>vs</i>. 59.1 years in losartan to 62.9 <i>vs</i>. 63.6 years in nifedipine). Higher hospitalization rates among originator initiators were observed for three calcium channel blockers (hazard ratio[95% CI]: amlodipine, 3.18[1.43, 7.11]; felodipine, 3.60[1.63, 7.98]; and nifedipine, 3.86[1.26, 11.81]; respectively). The remaining four out of seven drugs of the clinical endpoint estimates showed comparable outcomes between originator products and generics (hazard ratio[95% CI]: irbesartan, 1.19[0.50, 2.84]; losartan, 1.84[0.84, 4.07]; valsartan, 2.04[0.72, 5.78]; and metoprolol, 1.25[0.56, 2.80]; respectively). Higher median annual hypertension-related medical costs were observed in originator initiators (all <i>p</i> &lt; 0.001), except for metoprolol (<i>p</i> = 0.646). <b>Conclusion:</b> We observed comparable or even better clinical outcomes and less medical cost associated with the use of antihypertensive generics compared to originator counterparts. This could help increase patient and provider confidence in the efficacy of generic medicines to manage hypertension diseases.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Huang, Bai, Wushouer, Wang, Yang, Lin, Shen, Guan and Shi.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Tao</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bai</LastName>
            <ForeName>Lin</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wushouer</LastName>
            <ForeName>Haishaerjiang</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>International Research Center for Medicinal Administration, Peking University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zhiyuan</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Mingchun</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Hongbo</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Yinzhou District Center for Disease Control and Prevention, Ningbo, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Peng</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Yinzhou District Center for Disease Control and Prevention, Ningbo, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guan</LastName>
            <ForeName>Xiaodong</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>International Research Center for Medicinal Administration, Peking University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Luwen</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>International Research Center for Medicinal Administration, Peking University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Pharmacol</MedlineTA>
        <NlmUniqueID>101548923</NlmUniqueID>
        <ISSNLinking>1663-9812</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">antihypertenisve</Keyword>
        <Keyword MajorTopicYN="N">clinical outcome</Keyword>
        <Keyword MajorTopicYN="N">comparative effectiveness research</Keyword>
        <Keyword MajorTopicYN="N">generic</Keyword>
        <Keyword MajorTopicYN="N">originator</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>17</Day>
          <Hour>5</Hour>
          <Minute>8</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35295329</ArticleId>
        <ArticleId IdType="pmc">PMC8920543</ArticleId>
        <ArticleId IdType="doi">10.3389/fphar.2022.757398</ArticleId>
        <ArticleId IdType="pii">757398</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Austin P. C. (2011). Optimal Caliper Widths for Propensity-Score Matching when Estimating Differences in Means and Differences in Proportions in Observational Studies. Pharm. Stat.
10 (2), 150–161. 10.1002/pst.433
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pst.433</ArticleId>
            <ArticleId IdType="pmc">PMC3120982</ArticleId>
            <ArticleId IdType="pubmed">20925139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Austin P. C. (2013). The Performance of Different Propensity Score Methods for Estimating Marginal hazard Ratios. Stat. Med.
32 (16), 2837–2849. 10.1002/sim.5705
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/sim.5705</ArticleId>
            <ArticleId IdType="pmc">PMC3747460</ArticleId>
            <ArticleId IdType="pubmed">23239115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Babar Z. U., Grover P., Stewart J., Hogg M., Short L., Seo H. G., et al.  (2011). Evaluating Pharmacists' Views, Knowledge, and Perception Regarding Generic Medicines in New Zealand. Res. Soc. Adm Pharm
7 (3), 294–305. 10.1016/j.sapharm.2010.06.004
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.sapharm.2010.06.004</ArticleId>
            <ArticleId IdType="pubmed">21272551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Banerjee A., Khandelwal S., Nambiar L., Saxena M., Peck V., Moniruzzaman M., et al.  (2016). Health System Barriers and Facilitators to Medication Adherence for the Secondary Prevention of Cardiovascular Disease: a Systematic Review. Open Heart
3 (2), e000438. 10.1136/openhrt-2016-000438
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/openhrt-2016-000438</ArticleId>
            <ArticleId IdType="pmc">PMC5030589</ArticleId>
            <ArticleId IdType="pubmed">27738515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Corrao G., Soranna D., La Vecchia C., Catapano A., Agabiti-Rosei E., Gensini G., et al.  (2014). Medication Persistence and the Use of Generic and Brand-Name Blood Pressure-Lowering Agents. J. Hypertens.
32 (5), 1146–1153. 10.1097/HJH.0000000000000130
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/HJH.0000000000000130</ArticleId>
            <ArticleId IdType="pubmed">24569417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Corrao G., Zambon A., Parodi A., Poluzzi E., Baldi I., Merlino L., et al.  (2008). Discontinuation of and Changes in Drug Therapy for Hypertension Among Newly-Treated Patients: a Population-Based Study in Italy. J. Hypertens.
26 (4), 819–824. 10.1097/HJH.0b013e3282f4edd7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/HJH.0b013e3282f4edd7</ArticleId>
            <ArticleId IdType="pubmed">18327094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Desai R. J., Sarpatwari A., Dejene S., Khan N. F., Lii J., Rogers J. R., et al.  (2019). Comparative Effectiveness of Generic and Brand-Name Medication Use: A Database Study of US Health Insurance Claims. Plos Med.
16 (3), e1002763. 10.1371/journal.pmed.1002763
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pmed.1002763</ArticleId>
            <ArticleId IdType="pmc">PMC6415809</ArticleId>
            <ArticleId IdType="pubmed">30865626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dunne S. S., Dunne C. P. (2015). What Do People Really Think of Generic Medicines? A Systematic Review and Critical Appraisal of Literature on Stakeholder Perceptions of Generic Drugs. BMC Med.
13, 173. 10.1186/s12916-015-0415-3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12916-015-0415-3</ArticleId>
            <ArticleId IdType="pmc">PMC4520280</ArticleId>
            <ArticleId IdType="pubmed">26224091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dylst P., Simoens S. (2011). Does the Market Share of Generic Medicines Influence the price Level?: a European Analysis. Pharmacoeconomics
29 (10), 875–882. 10.2165/11585970-000000000-00000
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/11585970-000000000-00000</ArticleId>
            <ArticleId IdType="pubmed">21797288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gagne J. J., Choudhry N. K., Kesselheim A. S., Polinski J. M., Hutchins D., Matlin O. S., et al.  (2014). Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes: a Cohort Study. Ann. Intern. Med.
161 (6), 400–407. 10.7326/M13-2942
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/M13-2942</ArticleId>
            <ArticleId IdType="pubmed">25222387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gagne J. J., Kesselheim A. S., Choudhry N. K., Polinski J. M., Hutchins D., Matlin O. S., et al.  (2015). Comparative Effectiveness of Generic versus Brand-Name Antiepileptic Medications. Epilepsy Behav.
52 (Pt A), 14–18. 10.1016/j.yebeh.2015.08.014
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yebeh.2015.08.014</ArticleId>
            <ArticleId IdType="pubmed">26386779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Godman B., Fadare J., Kwon H. Y., Dias C. Z., Kurdi A., Dias Godói I. P., et al.  (2021). Evidence-based Public Policy Making for Medicines across Countries: Findings and Implications for the Future. J. Comp. Eff. Res.
10 (12), 1019–1052. 10.2217/cer-2020-0273
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/cer-2020-0273</ArticleId>
            <ArticleId IdType="pubmed">34241546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Godman B., Wettermark B., van Woerkom M., Fraeyman J., Alvarez-Madrazo S., Berg C., et al.  (2014). Multiple Policies to Enhance Prescribing Efficiency for Established Medicines in Europe with a Particular Focus on Demand-Side Measures: Findings and Future Implications. Front. Pharmacol.
5, 106. 10.3389/fphar.2014.00106
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2014.00106</ArticleId>
            <ArticleId IdType="pmc">PMC4060455</ArticleId>
            <ArticleId IdType="pubmed">24987370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Haas J. S., Phillips K. A., Gerstenberger E. P., Seger A. C. (2005). Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997-2000. Ann. Intern. Med.
142 (11), 891–897. 10.7326/0003-4819-142-11-200506070-00006
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/0003-4819-142-11-200506070-00006</ArticleId>
            <ArticleId IdType="pubmed">15941695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ho P. M., Bryson C. L., Rumsfeld J. S. (2009). Medication Adherence: its Importance in Cardiovascular Outcomes. Circulation
119 (23), 3028–3035. 10.1161/CIRCULATIONAHA.108.768986
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.768986</ArticleId>
            <ArticleId IdType="pubmed">19528344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Huang B., Barber S. L., Xu M., Cheng S. (2017). Make up a Missed Lesson-New Policy to Ensure the Interchangeability of Generic Drugs in China. Pharmacol. Res. Perspect.
5 (3), e00318. 10.1002/prp2.318
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/prp2.318</ArticleId>
            <ArticleId IdType="pmc">PMC5464346</ArticleId>
            <ArticleId IdType="pubmed">28603636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Husain M. J., Datta B. K., Kostova D., Joseph K. T., Asma S., Richter P., et al.  (2020). Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability. J. Am. Heart Assoc.
9 (9), e015302. 10.1161/JAHA.119.015302
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/JAHA.119.015302</ArticleId>
            <ArticleId IdType="pmc">PMC7428558</ArticleId>
            <ArticleId IdType="pubmed">32338557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jiang B., Wang H., Zhou L., Shi L., Nie Y. (2020). Pharmacists' Perceptions of Generic Drugs in China. J. Chin. Pharm. Sci.
29 (5), 364–368. </Citation>
        </Reference>
        <Reference>
          <Citation>
Kesselheim A. S., Misono A. S., Lee J. L., Stedman M. R., Brookhart M. A., Choudhry N. K., et al.  (2008). Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease: a Systematic Review and Meta-Analysis. Jama
300 (21), 2514–2526. 10.1001/jama.2008.758
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2008.758</ArticleId>
            <ArticleId IdType="pmc">PMC2713758</ArticleId>
            <ArticleId IdType="pubmed">19050195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Leclerc J., Thibault M., Midiani Gonella J., Beaudoin C., Sampalis J. (2020). Are Generic Drugs Used in Cardiology as Effective and Safe as Their Brand-Name Counterparts? A Systematic Review and Meta-Analysis. Drugs
80 (7), 697–710. 10.1007/s40265-020-01296-x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40265-020-01296-x</ArticleId>
            <ArticleId IdType="pubmed">32279239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lewington S., Lacey B., Clarke R., Guo Y., Kong X. L., Yang L., et al.  (2016). The Burden of Hypertension and Associated Risk for Cardiovascular Mortality in China. JAMA Intern. Med.
176 (4), 524–532. 10.1001/jamainternmed.2016.0190
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamainternmed.2016.0190</ArticleId>
            <ArticleId IdType="pubmed">26975032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lin D. Y., Wei L. J. (1989). The Robust Inference for the Cox Proportional Hazards Model. J. Am. Stat. Assoc.
84 (408), 1074–1078. 10.1080/01621459.1989.10478874
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/01621459.1989.10478874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lin H., Tang X., Shen P., Zhang D., Wu J., Zhang J., et al.  (2018). Using Big Data to Improve Cardiovascular Care and Outcomes in China: a Protocol for the Chinese Electronic Health Records Research in Yinzhou (CHERRY) Study. BMJ Open
8 (2), e019698. 10.1136/bmjopen-2017-019698
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2017-019698</ArticleId>
            <ArticleId IdType="pmc">PMC5829949</ArticleId>
            <ArticleId IdType="pubmed">29440217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lu J., Lu Y., Wang X., Li X., Linderman G. C., Wu C., et al.  (2017). Prevalence, Awareness, Treatment, and Control of Hypertension in China: Data from 1·7 Million Adults in a Population-Based Screening Study (China PEACE Million Persons Project). Lancet
390 (10112), 2549–2558. 10.1016/S0140-6736(17)32478-9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(17)32478-9</ArticleId>
            <ArticleId IdType="pubmed">29102084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lund J. L., Richardson D. B., Stürmer T. (2015). The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary Application. Curr. Epidemiol. Rep.
2 (4), 221–228. 10.1007/s40471-015-0053-5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40471-015-0053-5</ArticleId>
            <ArticleId IdType="pmc">PMC4778958</ArticleId>
            <ArticleId IdType="pubmed">26954351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mann B. S., Barnieh L., Tang K., Campbell D. J., Clement F., Hemmelgarn B., et al.  (2014). Association between Drug Insurance Cost Sharing Strategies and Outcomes in Patients with Chronic Diseases: a Systematic Review. PLoS One
9 (3), e89168. 10.1371/journal.pone.0089168
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0089168</ArticleId>
            <ArticleId IdType="pmc">PMC3965394</ArticleId>
            <ArticleId IdType="pubmed">24667163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Manzoli L., Flacco M. E., Boccia S., D'Andrea E., Panic N., Marzuillo C., et al.  (2016). Generic versus Brand-Name Drugs Used in Cardiovascular Diseases. Eur. J. Epidemiol.
31 (4), 351–368. 10.1007/s10654-015-0104-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10654-015-0104-8</ArticleId>
            <ArticleId IdType="pmc">PMC4877434</ArticleId>
            <ArticleId IdType="pubmed">26620809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mishuk A. U., Fasina I., Qian J. (2020). Impact of U.S. Federal and State Generic Drug Policies on Drug Use, Spending, and Patient Outcomes: A Systematic Review. Res. Soc. Adm Pharm
16 (6), 736–745. 10.1016/j.sapharm.2019.08.031
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.sapharm.2019.08.031</ArticleId>
            <ArticleId IdType="pubmed">31445986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
National Medical Products Administration (2020). Data Query: National Medical Products Administration. [cited 2020 Mar 14]. Available from: http://app1.sfda.gov.cn/datasearchcnda/face3/dir.html?WxUg5ztDmi=1584176709193#maodian1
. </Citation>
        </Reference>
        <Reference>
          <Citation>
Ngo S. N., Stupans I., McKinnon R. A. (2013). Generic Substitution in the Treatment of Epilepsy: Patient Attitudes and Perceptions. Epilepsy Behav.
26 (1), 64–66. 10.1016/j.yebeh.2012.10.032
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yebeh.2012.10.032</ArticleId>
            <ArticleId IdType="pubmed">23220461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Normand S. T., Landrum M. B., Guadagnoli E., Ayanian J. Z., Ryan T. J., Cleary P. D., et al.  (2001). Validating Recommendations for Coronary Angiography Following Acute Myocardial Infarction in the Elderly: a Matched Analysis Using Propensity Scores. J. Clin. Epidemiol.
54 (4), 387–398. 10.1016/s0895-4356(00)00321-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0895-4356(00)00321-8</ArticleId>
            <ArticleId IdType="pubmed">11297888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shrank W. H., Choudhry N. K., Agnew-Blais J., Federman A. D., Liberman J. N., Liu J., et al.  (2010). State Generic Substitution Laws Can Lower Drug Outlays under Medicaid. Health Aff. (Millwood)
29 (7), 1383–1390. 10.1377/hlthaff.2009.0424
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1377/hlthaff.2009.0424</ArticleId>
            <ArticleId IdType="pmc">PMC3103121</ArticleId>
            <ArticleId IdType="pubmed">20606192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shrank W. H., Hoang T., Ettner S. L., Glassman P. A., Nair K., DeLapp D., et al.  (2006). The Implications of Choice: Prescribing Generic or Preferred Pharmaceuticals Improves Medication Adherence for Chronic Conditions. Arch. Intern. Med.
166 (3), 332–337. 10.1001/archinte.166.3.332
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archinte.166.3.332</ArticleId>
            <ArticleId IdType="pubmed">16476874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Simoens S., Sinnaeve P. R. (2014). Patient Co-payment and Adherence to Statins: a Review and Case Studies. Cardiovasc. Drugs Ther.
28 (1), 99–109. 10.1007/s10557-013-6497-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10557-013-6497-2</ArticleId>
            <ArticleId IdType="pubmed">24150747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sinnott S. J., Buckley C., O'Riordan D., Bradley C., Whelton H. (2013). The Effect of Copayments for Prescriptions on Adherence to Prescription Medicines in Publicly Insured Populations; a Systematic Review and Meta-Analysis. PLoS One
8 (5), e64914. 10.1371/journal.pone.0064914
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0064914</ArticleId>
            <ArticleId IdType="pmc">PMC3665806</ArticleId>
            <ArticleId IdType="pubmed">23724105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Su M., Zhang Q., Bai X., Wu C., Li Y., Mossialos E., et al.  (2017). Availability, Cost, and Prescription Patterns of Antihypertensive Medications in Primary Health Care in China: a Nationwide Cross-Sectional Survey. Lancet
390 (10112), 2559–2568. 10.1016/S0140-6736(17)32476-5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(17)32476-5</ArticleId>
            <ArticleId IdType="pubmed">29102087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sundararajan V., Quan H., Halfon P., Fushimi K., Luthi J. C., Burnand B., et al.  (2007). Cross-national Comparative Performance of Three Versions of the ICD-10 Charlson index. Med. Care
45 (12), 1210–1215. 10.1097/MLR.0b013e3181484347
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MLR.0b013e3181484347</ArticleId>
            <ArticleId IdType="pubmed">18007172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Toverud E. L., Hartmann K., Håkonsen H. (2015). A Systematic Review of Physicians' and Pharmacists' Perspectives on Generic Drug Use: What Are the Global Challenges?
Appl. Health Econ. Health Pol.
13 Suppl 1 (Suppl. 1Suppl 1), S35–S45. 10.1007/s40258-014-0145-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40258-014-0145-2</ArticleId>
            <ArticleId IdType="pmc">PMC4519583</ArticleId>
            <ArticleId IdType="pubmed">25963230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vrijens F., Van de Voorde C., Farfan-Portet M. I., Vander Stichele R. (2012). Patient Socioeconomic Determinants for the Choice of the Cheapest Molecule within a Cluster: Evidence from Belgian Prescription Data. Eur. J. Health Econ.
13 (3), 315–325. 10.1007/s10198-011-0367-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10198-011-0367-2</ArticleId>
            <ArticleId IdType="pmc">PMC3343241</ArticleId>
            <ArticleId IdType="pubmed">22139141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang J. G., Chia Y. C., Chen C. H., Park S., Hoshide S., Tomitani N., et al.  (2020). What Is New in the 2018 Chinese Hypertension Guideline and the Implication for the Management of Hypertension in Asia?
J. Clin. Hypertens. (Greenwich)
22 (3), 363–368. 10.1111/jch.13803
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jch.13803</ArticleId>
            <ArticleId IdType="pmc">PMC8029728</ArticleId>
            <ArticleId IdType="pubmed">31955513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Who (2010). Cost Savings of Switching Private Sector Consumption from Originator Brands to Generic Equivalents. Geneva: World Health Organization. </Citation>
        </Reference>
        <Reference>
          <Citation>
Yang Y., Zhou X., Gao S., Lin H., Xie Y., Feng Y., et al.  (2018). Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China. Drug Saf.
41 (1), 125–137. 10.1007/s40264-017-0589-z
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40264-017-0589-z</ArticleId>
            <ArticleId IdType="pubmed">28815480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zeng W. (2013). A price and Use Comparison of Generic versus Originator Cardiovascular Medicines: a Hospital Study in Chongqing, China. BMC Health Serv. Res.
13 (1), 390. 10.1186/1472-6963-13-390
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1472-6963-13-390</ArticleId>
            <ArticleId IdType="pmc">PMC3851002</ArticleId>
            <ArticleId IdType="pubmed">24093493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhao Y., Mahal A. S., Haregu T. N., Katar A., Oldenburg B., Zhang L. (2019). Trends and Inequalities in the Health Care and Hypertension Outcomes in China, 2011 to 2015. Int. J. Environ. Res. Public Health
16 (22), 4578. 10.3390/ijerph16224578
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijerph16224578</ArticleId>
            <ArticleId IdType="pmc">PMC6888605</ArticleId>
            <ArticleId IdType="pubmed">31752338</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
